1. Background {#sec1}
=============

Idiopathic or primary dilated cardiomyopathy (DCM) is one of the leading causes of heart failure with high morbidity and mortality \[[@B1], [@B2]\]. The prevalence of DCM is 36.5 cases per 100,000 individuals, and 30--50% of all cases are diagnosed as a familial form of DCM \[[@B2]--[@B4]\]. Recent studies have reported that more than 40 genes, including 2 X-linked genes, are associated with DCM \[[@B5], [@B6]\]. In the vast majority of cases, these genes encode for sarcomeric contractile proteins such as troponin T (*TNNT2*), troponin I (*TNNI3*), and cardiac *α*-actin (ACTC) \[[@B7], [@B8]\].

The*TNNT2* gene (OMIM number ∗191045) encodes the thin-filament contractile protein cardiac troponin T, which links the troponin complex to tropomyosin in the sarcomere \[[@B9]\].*TNNT2* contains 16 exons, is located on chromosome 1q32, and comprises 25 kb of the genome. Recent data have indicated that*TNNT2* mutations are associated with DCM and that the overall frequency of*TNNT2* mutations in familial DCM is approximately 3--6% \[[@B10], [@B11]\]. In our laboratory, we found a significant association between tagging SNPs rs3729547, rs3729843 of*TNNT2* and DCM in the Chinese Han population \[[@B12]\]. In the present study, we further explored additional variants in DCM patients by sequencing an approximately 4 kb (3992 bp) DNA fragment covering the rs3729843 and rs3729547 mutations. We identified 6 novel*TNNT2* mutations in DCM patients, including a G12026T (c.252 G\>T) missense mutation (Leu84Phe), 5 novel mutations in introns, and 2 novel single-nucleotide polymorphisms (SNP) (c.192 + 353 C\>A, c.192 + 463 G\>A).

2. Materials and Methods {#sec2}
========================

2.1. Subjects and Selection of Tagging SNPs {#sec2.1}
-------------------------------------------

This case-control study enrolled 103 unrelated DCM patients from the Fuwai Hospital. The clinical diagnosis of DCM was made in accordance with revised criteria \[[@B2]\]. Primary DCM was defined as systolic dysfunction (left ventricular (LV) ejection fraction \<50%) with or without LV dilation in the absence of an apparent secondary cause of cardiomyopathy (such as congenital heart disease, ischemic heart disease, uncontrolled hypertension, significant valvular disease, glycogen storage disease, arrhythmogenic right ventricular cardiomyopathy, or concomitant complex congenital heart disease). Coronaroangiography was performed in all patients and patients with coronary artery disease were excluded. A total of 192 healthy, unrelated individuals from a routine health survey were enrolled as controls. This study was approved by the Ethics Committee of Fuwai Hospital. Subjects were informed of the study aims and provided written, informed consent prior to participating.

2.2. Samples {#sec2.2}
------------

Blood samples were collected via puncture of the cubital vein. Tubes with ethylene diamine tetra acetic acid were used for DNA analysis. Blood samples were stored at 4°C and DNA isolation was performed by a modified salting out procedure \[[@B13]\] within a week of collection.

2.3. DNA Sequencing {#sec2.3}
-------------------

Based on the SNP and linkage disequilibrium analysis of*TNNT2* in our recent study in DCM patients \[[@B12]\], an approximately 4-kilo-base (kb) fragment of*TNNT2* located at chr.201333582-201337484 was selected, and the fragment included exons 6, 7, 8, 9, and 10 and introns 5, 6, 7, 8, 9, and 10. The*TNNT2* fragment was amplified by PCR with primers (primer sequences available on request). Products were then sequenced using an ABI 3730 DNA Sequencer (Applied Biosystems, Foster City, CA). The DNA sequence was viewed and analyzed using the Sequencher computer program (Gene Codes Corporation, Ann Arbor, MI).

2.4. Statistical Analysis {#sec2.4}
-------------------------

Differences in the distributions of selected variables and*TNNT2* genotypes between cases and controls were evaluated using the chi-square (*χ* ^2^) test and continuous variables were analyzed using the independent-samples Student\'s*t*-test. The correlation between the*TNNT2* genotype and the risk of DCM was estimated by using logistic regression analysis to compute odds ratios (ORs) and 95% confidence intervals (CIs). The *χ* ^2^ test was used to determine Hardy-Weinberg equilibrium among control subjects. All statistical analyses were performed with SPSS 16.0 (SPSS Inc., Chicago, IL, USA) and a *P* value of \<0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Characteristics of the Study Cohort {#sec3.1}
----------------------------------------

The study included 295 subjects, consisting of 103 patients with DCM and 192 healthy control subjects; 4 patients and 3 control subjects were excluded from analyses due to indeterminate sequence results. A total of 79.4% of control subjects were males with a mean age of 54.0 ± 3.6 years. Patients with DCM were of a similar age to controls (51.6 ± 12.0 years; *t* = 1.700, *P* = 0.092) and were made up of a similar percentage of males (77.3%; *χ* ^2^ = 0.160, *P* = 0.689). In addition, 43.3% of DCM patients were smokers. There were no pregnant or peripartum subjects in this study. DCM patients were defined as having systolic dysfunction (LV ejection fraction \<50%), LV dilation detected by echocardiogram, and no apparent secondary cause of cardiomyopathy. In DCM patients, the mean LV ejection fraction was 32.0 ± 8.4%, LV diameter was 67.7 ± 8.6 mm, and left atrium diameter was 42.7 ± 7.6 mm. The genotypic frequencies of each SNP in control subjects fit the assumption of Hardy-Weinberg equilibrium ([Table 1](#tab1){ref-type="table"}).

3.2. Identification of Mutations {#sec3.2}
--------------------------------

The screening of the 3992-nucleotide fragment of*TNNT2* led to the identification of one novel missense mutation. A single-nucleotide variant consisting of a G\>T transversion (TTG\>TTT) at nucleotide 12026 (G12026T, c.252 G\>T) ([Figure 1](#fig1){ref-type="fig"}) in exon 9 was found in one DCM patient and would substitute a phenylalanine for the normal leucine at residue 84 (Leu84Phe). This patient was diagnosed at the age of 43 and was clinically symptomatic of heart failure, with LV 60 mm and LV ejection fraction 31%. Additionally, this patient had a familial history of coronary heart disease. In addition, we also identified 5 mutations in introns 6, 7, 9, and 10 in a subset of the DCM patients ([Figure 1](#fig1){ref-type="fig"}). Their clinical data are shown in [Table 2](#tab2){ref-type="table"}.

3.3. Identification of Polymorphisms {#sec3.3}
------------------------------------

During sequence analysis, 11 known SNPs and two novel SNPs (c.192 + 353 C\>A, c.192 + 463 G\>A) were identified in both DCM patients and control samples. We compared the genotype and allele frequencies of the*TNNT2* SNPs between the DCM patients and control subjects. Our results showed that the allele of the two novel SNPs (c.192 + 353 C\>A, OR = 0.095, 95% CI = 0.013--0.714, *P* = 0.022; c.192 + 463 G\>A, OR = 0.090, 95% CI = 0.012--0.675, *P* = 0.019) and SNP rs3729843 (OR = 1.889, 95% CI = 1.252--2.852, *P* = 0.002) were significantly correlated with DCM. The allele and genotype frequencies of the 13 SNPs identified in both DCM patients and control subjects are shown in [Table 3](#tab3){ref-type="table"}, with corresponding results from statistical analysis.

4. Discussion {#sec4}
=============

In our study, we analyzed a 3992-nucleotide sequence of the*TNNT2* gene containing exons 6, 7, 8, 9, and 10 and introns 5, 6, 7, 8, 9, 10, and 11. We identified 6 novel*TNNT2* mutations in DCM patients, including a missense mutation (G12026T, c.252 G\>T, Leu84Phe) and 5 novel intronic mutations. We also found that the genotype of two novel single-nucleotide polymorphisms (c.192 + 353 C\>A, c.192 + 463 G\>A) and the previously identified rs3729843 \[[@B12]\] were correlated with DCM. These data indicate that*TNNT2* variants are associated with DCM in Chinese population. To our knowledge, the two novel SNPs and the six mutations, in which five are in intron and one is in exon, have not been reported in dilated cardiomyopathy before.

Dilated cardiomyopathy is an important cause of heart failure and the leading indication for cardiac transplantation worldwide \[[@B14]\]. With careful evaluation of relatives, familial disease can be identified in approximately 30% of patients with idiopathic DCM \[[@B15]\]. Genetic characterization of DCM has been a challenging task owing to incomplete knowledge of the genes involved in the disease as well as difficulties in determining the clinical significance of DNA variants identified in patients. More than 40 different genes have been implicated in the pathophysiology of DCM \[[@B5], [@B6]\], and*TNNT2* mutations in familial DCM are approximately 3--6% \[[@B10], [@B11]\].

Cardiac troponin (cTn) is made up of three distinct subunits, each named according to its function: cardiac troponin I (cTnI) can inhibit the actomyosin ATPase activity independently of the other Tn subunits; cardiac troponin C (cTnC) binds Ca^2+^ to a low affinity Ca^2+^-specific binding site, relieving the cTnI inhibition; and cardiac troponin T (cTnT) binds the entire cTn complex to tropomyosin (Tm) \[[@B16], [@B17]\]. Recent studies have suggested that cardiac TnT is essential not only for the structural integrity of the troponin complex but also for sarcomere assembly and cardiac contractility \[[@B18]\]. The troponin complex is a calcium sensor that regulates the contraction of striated muscle and modulates actomyosin ATPase activity and force \[[@B19]\]. Over the past decade, mutations in the*TNNT2* gene have been found to be associated with familial HCM and DCM \[[@B3], [@B10], [@B11], [@B20]--[@B22]\]. Many studies in reconstituted systems have provided valuable information on the functional effects of disease-associated mutations in TnT \[[@B23]--[@B28]\].

Independent laboratories have consistently observed that changes in Ca^2+^-sensitivity, ATPase activity, or force development due to cTn mutations decrease in DCM \[[@B23], [@B24]\]. All DCM mutations in cTnT (R131W, R141W, R205L, and ΔK210) showed decreases in ATPase activation \[[@B25]--[@B28]\]. Mutant transgenic mice expressing cTnT I79N show increased Ca^2+^ sensitivity of force development and decreased force per cross-sectional area \[[@B24]\]. The observed decrease in force per cross-sectional area by this mutation has been reported by different groups \[[@B29], [@B30]\]. Lin and colleagues \[[@B31]\] demonstrated that transgenic mice carrying either cTnT mutations F110I or R278C displayed significant increases in energy cost. Alterations in the energy cost could be explained as an increase in the rate of dissociation of myosin cross bridges and/or a decrease in the average force per cross bridge. The functional effects of a cTnT mutation (ΔK210) linked to DCM have been explored in reconstituted systems and in animal models. In vitro studies showed that cTnT ΔK210 exchanged in skinned porcine cardiac fibers decreased the relative maximal force \[[@B27], [@B29]\].

In the present study, we found a missense mutation (G12026T, c.252 G\>T, Leu84Phe) in one DCM patient. This mutation was first reported in DCM patients and resulted in the substitution of a phenylalanine for the normal leucine at residue 84 in TnT. We used the website <http://www.proteinmodelportal.org/query/pdb> to query the crystal structure of the 52 kDa domain of human TNNT2; however, the crystal structure around the 84th amino acid in the protein is not reported up to now. Therefore, we estimate the damage of TNNT2 Leu 84 Phe transition using website <http://genetics.bwh.harvard.edu/pph/>. The result indicated that the mutation is predicted to be probably damaging with a score of 0.992 (total score is equal to one; sensitivity 0.7; specificity 0.97). The 84th amino acid in TNNT2 is a very conserved site in human, rat, mice, and zebrafish. The 84th amino acid was substituted by phenylalanine which function and structure with a benzene ring is different from leucine. Therefore, this mutation might contribute to the occurrence of dilated cardiomyopathy.

In addition, we found 5 intronic mutations in DCM patients as well as a significant association between the genotypes of 2 novel SNPs and rs3729843 with DCM. Although there were no encoding amino acid changes in these mutations and polymorphisms, numerous functional roles for introns have been elucidated; these functions include augmenting proteome diversity by enabling alternative splicing, enhancing gene expression, and harboring various*cis-* and*trans*-regulatory elements \[[@B32]--[@B37]\]. In addition, some studies also showed that some polymorphisms in noncoding regions may influence the expression level of the encoded protein, thus resulting in a more subtle variation in the associated phenotype \[[@B38]\]. These results suggest that*TNNT2* mutations and polymorphisms may play an important role in DCM in the Chinese Han population. However, additional functional analyses are needed to confirm the role of these variants in DCM pathogenesis.

In conclusion, based on the sequence analysis of*TNNT2* in DCM patients, the present study identified 6 novel*TNNT2* variants, a missense mutation (G12026T, c.252 G\>T, Leu84Phe), 5 mutations in introns, SNP rs3729843, and 2 novel single-nucleotide polymorphisms (c.192+353 C\>A, c.192+463 G\>A). These TNNT2 variants might be associated with DCM in the Chinese population.

5. Limitations of the Study {#sec5}
===========================

There are clear limitations to the feasibility and practicality of screening for mutations in only one gene. Genetic analysis as performed in this study, which is limited to only a small number of potentially involved exons, does not seem to be applicable. It was impossible to screen all other genes associated with DCM, so we cannot exclude the possibility that some patients were compound heterozygotes. Functional analyses of mutations are required to confirm the findings in this study. In addition, most of patients and many SNPs are the same as those in the previous study \[[@B12]\] although the detecting method is different.
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###### 

The sequences of the primers used to amplify the 4 kb region in *TNNT2*.

  Markers    Sequences of PCR primers   Tm   Length
  ---------- -------------------------- ---- --------
  TNNT2-1F   CATGTTCTGTGGTGCCAGAC       57   899
  TNNT2-1R   TGCCACCAAGTTCTGTCCTC       58   
  TNNT2-2F   AGGAGGCTGAAGGTAAGGAT       55   691
  TNNT2-2R   ACACTCACGCAGTGTGGAAC       56   
  TNNT2-3F   AGGCCTTGTCACTGTGAAGC       58   573
  TNNT2-3R   TGCACGATTGGTGATGGAGT       59   
  TNNT2-4F   TGTGTACTGCACAAGCGTCTC      59   514
  TNNT2-4R   GTGCACAAGAGGCCAGGAAG       61   
  TNNT2-5F   ATAGGCATGGCGGCTTCA         60   862
  TNNT2-5R   ACAGCCACCGCTTACATCAA       59   
  TNNT2-6F   GGCAGTGCTGGAAGATTCTC       57   629
  TNNT2-6R   GGCCATCAGAGAATGTTAGG       55   
  TNNT2-7F   AATGAGTTGCAGGCGCTGAT       61   454
  TNNT2-7R   CTCCAGCCAGAGCAGCATGT       61   
  TNNT2-8F   CCTTGACTGCCAGAGCTGAG       58   559
  TNNT2-8R   GAGAAGGTGACATCGCAGGTA      59   

###### 

Mutations in *TNNT2* in DCM patients.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Markers       Exon/intron   Location of nucleotide change   Amino acid change   Number of patients   Gender   Age at diagnosis (years)   Family history                      LVEDD (mm)   LVEF (%)
  ------------- ------------- ------------------------------- ------------------- -------------------- -------- -------------------------- ----------------------------------- ------------ ----------
  c.163 + 107   Intron 6      201337183 C\>T                  Noncoding           1                    Male     37                         No                                  82           18

  c.163 + 342   Intron 6      201336948 C\>T                  Noncoding           1                    Male     30                         No                                  81           31

  c.199 + 512   Intron 7      201336387 A\>C                  Noncoding           1                    Male     59                         Suspensive coronary heart disease   60           45

  c.252         Exon 9        201334780 G\>T                  Leu 84 Phe          1                    Male     43                         Suspensive\                         60           31
                                                                                                                                           coronary heart disease                           

  c.294 + 143   Intron 9      201334595 G\>A                  Noncoding           1                    Male     45                         No                                  58           40

  c.411 + 376   Intron 10     201333948 A\>G                  Noncoding           1                    Male     62                         Suspensive cardiovascular disease   80           36
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction.

###### 

Genotype and allele frequencies of the SNPs in *TNNT2* in the DCM patients and control subjects.

  Marker            Genotype      *χ* ^2^, *P* value   Allele        *P* value           OR (95% CI)   Power                                              
  ----------------- ------------- -------------------- ------------- ------------------- ------------- ------------- ------------- ---------------------- -------
  rs45576939        A/A           A/G                  G/G                               A             G             0.173         0.235 (0.029, 1.889)   28%
   Patients         0 (0)         1 (0.01)             97 (0.99)     *χ* ^2^ = 2.231     1 (0.01)      195 (0.99)                                          
   Controls         0 (0)         8 (0.043)            179 (0.957)   *P* = 0.135         8 (0.021)     366 (0.979)                                         
  rs3729842         C/C           C/T                  T/T                               C             T             0.865         1.042 (0.651, 1.667)   5.4%
   Patients         74 (0.755)    16 (0.163)           8 (0.082)     *χ* ^2^ = 4.282     164 (0.837)   32 (0.163)                                          
   Controls         135 (0.722)   45 (0.241)           7 (0.037)     *P* = 0.118         315 (0.842)   59 (0.158)                                          
  rs3729843         A/A           A/G                  G/G                               A             G             ***0.002***   1.889 (1.252, 2.852)   85.2%
   Patients         11 (0.112)    33 (0.337)           54 (0.551)    *χ* ^2^ = 8.315     55 (0.281)    141 (0.719)                                         
   Controls         7 (0.037)     50 (0.267)           130 (0.695)   ***P*  =  0.004**   64 (0.171)    310 (0.829)                                         
  rs1892028         A/A           A/G                  G/G                               A             G             0.140         0.770 (0.544, 1.090)   31.3%
   Patients         31 (0.313)    54 (0.5)             14 (0.143)    *χ* ^2^ = 4.719     116 (0.586)   82 (0.414)                                          
   Controls         55 (0.294)    86 (0.460)           47 (0.251)    *P* = 0.094         196 (0.521)   180 (0.479)                                         
  rs10800775        C/C           C/T                  T/T                               C             T             0.152         0.766 (0.533, 1.103)   29.7%
   Patients         46 (0.465)    45 (0.455)           9 (0.090)     *χ* ^2^ = 2.142     137 (0.685)   63 (0.315)                                          
   Controls         73 (0.388)    89 (0.473)           26 (0.138)    *P* = 0.343         235 (0.625)   141 (0.375)                                         
  rs7544061         T/T           T/C                  C/C                               T             C             0.612         0.821 (0.383, 1.761)   73%
   Patients         0 (0)         10 (0.101)           89 (0.899)    *χ* ^2^ = 0.274     10 (0.051)    188 (0.949)                                         
   Controls         0 (0)         23 (0.116)           166 (0.834)   *P* = 0.601         23 (0.061)    355 (0.939)                                         
  rs3767545         A/A           A/G                  G/G                               A             G             0.294         1.680 (0.638, 4.424)   20.3%
   Patients         0 (0)         8 (0.081)            91 (0.919)    *χ* ^2^ = 1.160     8 (0.04)      190 (0.960)                                         
   Controls         0 (0)         9 (0.049)            175 (0.951)   *P* = 0.282         9 (0.024)     359 (0.976)                                         
  rs3729547         C/C           T/C                  T/T                               C             T             ***0.033***   0.679 (0.475, 0.970)   56.9%
   Patients         9 (0.092)     51 (0.520)           38 (0.388)    *χ* ^2^ = 5.679     69 (0.352)    127 (0.648)                                         
   Controls         37 (0.196)    94 (0.497)           58 (0.307)    *P* = 0.058         168 (0.444)   210 (0.556)                                         
  rs3767546         A/A           A/T                  T/T                               A             T             0.457         0.751 (0.353, 1.597)   10.6%
   Patients         0 (0)         10 (0.102)           89 (0.908)    *χ* ^2^ = 0.816     10 (0.051)    188 (0.949)                                         
   Controls         1 (0.005)     23 (0.122)           165 (0.873)   *P* = 0.665         25 (0.067)    353 (0.934)                                         
  rs117962659       C/C           C/A                  A/A                               C             A             0.186         1.920 (0.730, 5.049)   12.4%
   Patients         0 (0)         6 (0.061)            93 (0.939)    *χ* ^2^ = 0.895     6 (0.030)     192 (0.970)                                         
   Controls         1 (0.005)     15 (0.080)           172 (0.915)   *P* = 0.639         17 (0.045)    359 (0.955)                                         
  rs2275860         A/A           A/G                  G/G                               A             G             0.448         0.745 (0.351, 1.588)   10.8%
   Patients         1 (0.010)     8 (0.081)            90 (0.909)    *χ* ^2^ = 3.564     10 (0.051)    188 (0.949)                                         
   Controls         0 (0)         25 (0.133)           163 (0.867)   *P* = 0.168         25 (0.066)    351 (0.934)                                         
  c.192 + 353 C/A   C/C           C/A                  A/A                               C             A             ***0.022***   0.095 (0.013, 0.714)   87.2%
   Patients         98 (0.990)    1 (0.010)            0 (0)         *χ* ^2^ = 8.333     197 (0.995)   1 (0.005)                                           
   Controls         168 (0.898)   19 (0.102)           0 (0)         ***P*  =  0.004**   355 (0.949)   19 (0.051)                                          
  c.192 + 463 G/A   G/G           A/G                  A/A                               G             A             ***0.019***   0.090 (0.012, 0.675)   89.7%
   Patients         98 (0.99)     1 (0.01)             0 (0)         *χ* ^2^ = 8.925     197 (0.995)   1 (0.005)                                           
   Controls         167 (0.893)   20 (0.107)           0 (0)         ***P*  =  0.003**   354 (0.947)   20 (0.053)                                          

Note: OR: odds ratio, at which the minor allele was viewed as an exposure factor in this case-control study.
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